Penbrook Management’s Novartis NVS Stock Holding History

Penbrook Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$868K	Hold	5,540	–	–	0.55%	50
2026 Q1	$846K	Sell	5,540 -70	-1%	-$10.7K	0.64%	46
2025 Q4	$773K	Hold	5,610	–	–	0.53%	48
2025 Q3	$719K	Sell	5,610 -5,760	-51%	-$703K	0.5%	47
2025 Q2	$1.32M	Buy	11,370 +5,610	+97%	+$632K	0.5%	49
2025 Q1	$642K	Hold	5,760	–	–	0.49%	47
2024 Q4	$561K	Hold	5,760	–	–	0.38%	56
2024 Q3	$663K	Hold	5,760	–	–	0.43%	50
2024 Q2	$613K	Hold	5,760	–	–	0.37%	56
2024 Q1	$557K	Hold	5,760	–	–	0.35%	64
2023 Q4	$582K	Buy	5,760 +300	+5%	+$29K	0.39%	58
2023 Q3	$556K	Hold	5,460	–	–	0.41%	54
2023 Q2	$551K	Hold	5,460	–	–	0.4%	55
2023 Q1	$502K	Hold	5,460	–	–	0.38%	61
2022 Q4	$495K	Sell	5,460 -1,000	-15%	-$84.2K	0.42%	63
2022 Q3	$491K	Hold	6,460	–	–	0.42%	61
2022 Q2	$546K	Hold	6,460	–	–	0.43%	63
2022 Q1	$567K	Hold	6,460	–	–	0.37%	68
2021 Q4	$565K	Hold	6,460	–	–	0.34%	73
2021 Q3	$528K	Hold	6,460	–	–	0.33%	78
2021 Q2	$589K	Hold	6,460	–	–	0.35%	72
2021 Q1	$552K	Sell	6,460 -300	-4%	-$26.9K	0.4%	69
2020 Q4	$638K	Hold	6,760	–	–	0.49%	59
2020 Q3	$588K	Hold	6,760	–	–	0.51%	55
2020 Q2	$590K	Hold	6,760	–	–	0.58%	53
2020 Q1	$557K	Hold	6,760	–	–	0.71%	40
2019 Q4	$640K	Hold	6,760	–	–	0.62%	56
2019 Q3	$587K	Buy	6,760 +260	+4%	+$23.3K	0.64%	57
2019 Q2	$594K	Buy	6,500 +362	+6%	+$30.6K	0.64%	54
2019 Q1	$529K	Hold	6,138	–	–	0.55%	64
2018 Q4	$472K	Hold	6,138	–	–	0.54%	59
2018 Q3	$474K	Hold	6,138	–	–	0.45%	70
2018 Q2	$415K	Hold	6,138	–	–	0.4%	78
2018 Q1	$445K	Hold	6,138	–	–	0.44%	73
2017 Q4	$462K	Buy	+6,138	New	+$463K	0.42%	74
2016 Q3	$434K	Hold	6,138	–	–	0.47%	70
2016 Q2	$454K	Hold	6,138	–	–	0.5%	68
2016 Q1	$398K	Hold	6,138	–	–	0.44%	74
2015 Q4	$473K	Hold	6,138	–	–	0.49%	70
2015 Q3	$506K	Hold	6,138	–	–	0.54%	67
2015 Q2	$541K	Buy	6,138 +335	+6%	+$30.7K	0.51%	71
2015 Q1	$513K	Hold	5,803	–	–	0.46%	78
2014 Q4	$482K	Hold	5,803	–	–	0.43%	84
2014 Q3	$489K	Hold	5,803	–	–	0.45%	79
2014 Q2	$471K	Sell	5,803 -5,803	-50%	-$456K	0.42%	80
2014 Q1	$860K	Buy	11,606 +5,803	+100%	+$423K	0.41%	75
2013 Q4	$418K	Buy	+5,803	New	+$403K	0.41%	78

Other funds holding NVS

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GGI

Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Penbrook Management's NVS Position: Q2 2026 in Review

Penbrook Management held its Novartis (NVS) position steady in Q2 2026 at 5,540 shares worth $868K. The position accounts for 0.55% of the portfolio, ranked #50.

Penbrook Management first reported a position in NVS in Q4 2013 and has held it in 47 quarters since. The position peaked at $1.32M in Q2 2025. 509 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Penbrook Management held 5,540 shares of Novartis worth $868K as of Q2 2026.
Penbrook Management left its Novartis share count unchanged in Q2 2026.
Novartis made up 0.55% of Penbrook Management's portfolio in Q2 2026, its #50 holding.
Penbrook Management first reported a position in Novartis in Q4 2013 and has held it in 47 quarters since.
Penbrook Management's Novartis position peaked at $1.32M in Q2 2025.
509 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Penbrook Management's 13F filing for Q2 2026, filed 23 Jul 2026.